Company intelligence / Profile preview

21org

Ownership: Private
Development stage: Other

Overview

21st.BIO is a Danish biotech company founded in 2020 that acts as a technology and service partner to precision fermentation companies. It enables customers to scale up from molecule innovation to large-scale cost-effective production of proteins and peptides using advanced microbial cell factory platforms. The company's core technologies are partly licensed from Novozymes, leveraging decades of enzyme manufacturing expertise. In 2023, it opened its first U.S. R&D facility in Davis, California. No direct clinical results as the company does not run therapeutic programs.

Modalities: ProteinPeptides
Industry: Non-Drug Biotech

Partnerships

Novozymes (technology licensing partner)Novo Holdings (investor/strategic relationship)

Beyond the preview

Go deeper on 21org.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 21org.

Explore the full profile